Treating solid tumors with TCR-based chimeric antigen receptor targeting extra domain B-containing fibronectin

BACKGROUND: The suppression of chimeric antigen receptor (CAR) T cells by the tumor microenvironment (TME) is a crucial obstacle in the T-cell-based treatment of solid tumors. Extra domain B (EDB)-fibronectin is an oncofetal antigen expressed on the endothelium layer of the neovasculature and cancer...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Zhijie, Liu, Chang, Wang, Muhan, Sun, Rongcheng, Yang, Zhe, Hua, Zhen, Wu, Yushuang, Wu, Mengting, Wang, Hang, Qiu, Wen, Yin, Hongping, Yang, Meijia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Immune Cell Therapies and Immune Cell Engineering
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10432677/
https://www.ncbi.nlm.nih.gov/pubmed/37586774
http://dx.doi.org/10.1136/jitc-2023-007199

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10432677/
https://www.ncbi.nlm.nih.gov/pubmed/37586774
http://dx.doi.org/10.1136/jitc-2023-007199

Ejemplares similares